Evidence map›Paper›PMID 34481984›Full record

ArticleHeart rhythm2021

Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk.

Alexander Burashnikov, Hector Barajas-Martinez, Robert Cox, Mark A Demitrack, Michael J Fossler, Michael Kramer, Robert B Kleiman, Peter Kowey, Charles Antzelevitch

Open access · greenAbstract read
In one paragraph

Article in Heart rhythm, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. PersonalizedFrontiers in physiology · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alexander BurashnikovLankenau Institute for Medical Research, Wynnewood, Pennsylvania; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Hector Barajas-MartinezLankenau Institute for Medical Research, Wynnewood, Pennsylvania.
Robert CoxLankenau Institute for Medical Research, Wynnewood, Pennsylvania.
Mark A DemitrackTrevena Inc., Chesterbrook, Pennsylvania.
Michael J FosslerTrevena Inc., Chesterbrook, Pennsylvania.
Michael KramerTrevena Inc., Chesterbrook, Pennsylvania.
Robert B KleimaneResearch Technology Inc, Philadelphia, Pennsylvania.
Peter KoweyLankenau Institute for Medical Research, Wynnewood, Pennsylvania; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; Lankenau Heart Institute, Main Line Health System, Wynnewood, Pennsylvania.
Charles AntzelevitchLankenau Institute for Medical Research, Wynnewood, Pennsylvania; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; Lankenau Heart Institute, Main Line Health System, Wynnewood, Pennsylvania. Electronic address: cantzelevitch@gmail.com.
Lankenau Institute for Medical Research · USERT (Germany) · DE

Funding

ELECTRICAL HETEROGENEITY AND CARDIAC ARRHYTHMIASR01HL047678 · NHLBI · MASONIC MEDICAL RESEARCH LABORATORY, INC · PI ANTZELEVITCH, CHARLES · 1993 to 2014
$5.7M
Development of a whole heart model of the J wave syndromes and novel approaches to pharmacologic management of associated life-threatening arrhythmiasR01HL152201 · NHLBI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI ANTZELEVITCH, CHARLES, DI DIEGO, JOSE M. · 2020 to 2023
$2.5M
Novel Approaches to Pharmacologic Management of Life-Threatening Arrhythmias Associated with the J Wave SyndromesR56HL138103 · NHLBI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI ANTZELEVITCH, CHARLES · 2018 to 2018
$413k
NHLBI NIH HHS R01 HL047678NHLBI NIH HHS R01 HL152201NHLBI NIH HHS R56 HL138103
6 · The paper itself

Abstract

backgroundOliceridine is a biased ligand at the μ-opioid receptor recently approved for the treatment of acute pain. In a thorough QT study, corrected QT (QTc) prolongation displayed peaks at 2.5 and 60 minutes after a supratherapeutic dose. The mean plasma concentration peaked at 5 minutes, declining rapidly thereafter.

objectiveThe purpose of this study was to examine the basis for the delayed effect of oliceridine to prolong the QTc interval.

methodsRepolarization parameters and tissue accumulation of oliceridine were evaluated in rabbit left ventricular wedge preparations over a period of 5 hours. The effects of oliceridine on ion channel currents were evaluated in human embryonic kidney and Chinese hamster ovary cells. Quinidine was used as a control.

resultsOliceridine and quinidine produced a progressive prolongation of the QTc interval and action potential duration over a period of 5 hours, paralleling slow progressive tissue uptake of the drugs. Oliceridine caused modest prolongation of these parameters, whereas quinidine produced a prominent prolongation of action potential duration and QTc interval as well as development of early afterdepolarization (after 2 hours), resulting in a high torsades de pointes score. The 50% inhibitory concentration values for the oliceridine inhibition of the rapidly activating delayed rectifier current (human ether a-go-go current) and late sodium channel current were 2.2 and 3.45 μM when assessed after traditional acute exposure but much lower after 3 hours of drug exposure.

conclusionOur findings suggest that a gradual increase of intracellular access of drugs to the hERG channels as a result of their intracellular uptake and accumulation can significantly delay effects on repolarization, thus confounding the assessment of QT interval prolongation and arrhythmic risk when studied acutely. The multi-ion channel effects of oliceridine, late sodium channel current inhibition in particular, point to a low risk of devloping torsades de pointes.

Indexed as

Arrhythmias, CardiacAnalgesics, OpioidAnimalsCell LineCricetulusERG1 Potassium ChannelHumansInhibitory Concentration 50Long QT SyndromeMembrane Transport ModulatorsQuinidineSpiro CompoundsThiophenesTissue DistributionVoltage-Gated Sodium Channel Blockers((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineAnalgesics, OpioidERG1 Potassium ChannelMembrane Transport ModulatorsQuinidineSpiro CompoundsThiophenesVoltage-Gated Sodium Channel BlockersAcquired long QT syndromeOpiatesOpioidsPharmacokinetic-pharmacodynamic modelsPharmacologyQuinidine

Identifiers

PMID34481984
PMCPMC8629933
OpenAlexW3196791221

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.